These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25425420)

  • 1. Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum.
    Banda NK; Mehta G; Chao Y; Wang G; Inturi S; Fossati-Jimack L; Botto M; Wu L; Moghimi SM; Simberg D
    Part Fibre Toxicol; 2014 Nov; 11():64. PubMed ID: 25425420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.
    Inturi S; Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
    ACS Nano; 2015 Nov; 9(11):10758-68. PubMed ID: 26488074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement opsonization of nanoparticles: Differences between humans and preclinical species.
    Li Y; Wang G; Griffin L; Banda NK; Saba LM; Groman EV; Scheinman R; Moghimi SM; Simberg D
    J Control Release; 2021 Oct; 338():548-556. PubMed ID: 34481928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.
    Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D
    Front Immunol; 2016; 7():418. PubMed ID: 27777575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.
    Banda NK; Levitt B; Wood AK; Takahashi K; Stahl GL; Holers VM; Arend WP
    Clin Exp Immunol; 2010 Jan; 159(1):100-8. PubMed ID: 19843088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties.
    Wang G; Inturi S; Serkova NJ; Merkulov S; McCrae K; Russek SE; Banda NK; Simberg D
    ACS Nano; 2014 Dec; 8(12):12437-49. PubMed ID: 25419856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.
    Harboe M; Garred P; Borgen MS; Stahl GL; Roos A; Mollnes TE
    Clin Exp Immunol; 2006 Jun; 144(3):512-20. PubMed ID: 16734621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
    Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
    J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
    Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D
    Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.
    Hamad I; Hunter AC; Szebeni J; Moghimi SM
    Mol Immunol; 2008 Dec; 46(2):225-32. PubMed ID: 18849076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of the lectin pathway of complement in human serum.
    Roos A; Bouwman LH; Munoz J; Zuiverloon T; Faber-Krol MC; Fallaux-van den Houten FC; Klar-Mohamad N; Hack CE; Tilanus MG; Daha MR
    Mol Immunol; 2003 Jan; 39(11):655-68. PubMed ID: 12493641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo.
    Chen F; Wang G; Griffin JI; Brenneman B; Banda NK; Holers VM; Backos DS; Wu L; Moghimi SM; Simberg D
    Nat Nanotechnol; 2017 May; 12(4):387-393. PubMed ID: 27992410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging.
    Unterweger H; Janko C; Schwarz M; Dézsi L; Urbanics R; Matuszak J; Őrfi E; Fülöp T; Bäuerle T; Szebeni J; Journé C; Boccaccini AR; Alexiou C; Lyer S; Cicha I
    Int J Nanomedicine; 2017; 12():5223-5238. PubMed ID: 28769560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wang G; Griffin JI; Inturi S; Brenneman B; Banda NK; Holers VM; Moghimi SM; Simberg D
    Front Immunol; 2017; 8():151. PubMed ID: 28239384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
    Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.
    Rohrer B; Coughlin B; Kunchithapautham K; Long Q; Tomlinson S; Takahashi K; Holers VM
    Mol Immunol; 2011 Mar; 48(6-7):e1-8. PubMed ID: 21257205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae.
    Ali YM; Kenawy HI; Muhammad A; Sim RB; Andrew PW; Schwaeble WJ
    PLoS One; 2013; 8(12):e82583. PubMed ID: 24349316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding to complement factors and activation of the alternative pathway by Acanthamoeba.
    Pumidonming W; Walochnik J; Dauber E; Petry F
    Immunobiology; 2011; 216(1-2):225-33. PubMed ID: 20627448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
    Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
    Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.